Medindia LOGIN REGISTER
Medindia

Drug Resistance of CLL in Bone Marrow, Lymph Nodes Identified

by Rathi Manohar on Dec 8 2010 7:52 PM

 Drug Resistance of CLL in Bone Marrow, Lymph Nodes Identified
Chronic lymphocytic leukemia (CLL) recurs in the lymph nodes and bone marrow even after being cleared from the bloodstream by chemotherapy.
An explanation for this occurence is disclosed in the findings of investigators at Dana-Farber Cancer Institute in Boston and will be reported at the American Society of Hematology (ASH) annual meeting in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center.

To uncover the reasons for CLL's resilience in the marrow and lymph nodes, the researchers employed a technique called BH3 profiling, which had been devised by senior author Anthony Letai, MD, PhD, and his Dana-Farber colleagues in 2005. The technique makes it possible to identify cancer cells that are less likely to undergo mitochondrial apoptosis (a form of programmed cell death involving cell structures called mitochondria) because of alterations in the Bcl-2 family of proteins. These abnormalities can make such cells less susceptible to both standard chemotherapy and novel, targeted agents.

In the current study, Letai and his associates found that when CLL cells from patients were grown with non-cancerous support cells from the bone marrow and lymph nodes, the CLL cells were more resistant to apoptosis – and hence harder to kill with treatment – than were CLL cells from the bloodstream. Using BH3 profiling, they discovered that although circulating CLL cells were likely to die by mitochondrial apoptosis in response to treatment, CLL cells grown among non-cancerous cells were much less likely to die this way. The presence of these normal cells, known as stroma, apparently helped the CLL cells survive, despite receiving treatment that would otherwise have resulted in their death.

"We hope that by clearly identifying the ability of stromal cells to reduce the CLL cells' capability to undergo apoptosis, we can exploit strategies to selectively target the 'help' that stromal cells give to CLL cells," says Letai.



Source-Eurekalert


Recommended Readings
Latest Research News
View All
Advertisement